title: The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
abstract: The aim of this study was to evaluate the efficacy, safety, and tolerability of weekly alendronate administration on male osteoporosis in Taiwan. This 6-month, randomized, open-label controlled trial enrolled 46 men with osteoporosis who were randomized to either 70 mg alendronate once weekly (n = 23) or control (n = 23). Bone mineral density (BMD) of lumbar spine and hip and biochemical bone turnover markers were measured; adverse events and tolerability were assessed. Subjects treated with alendronate showed a significant increase in BMD of 5.5% (vs. 2% in control group) at the lumbar spine and 2.7% (vs. 0.7%) at the femoral neck (P < 0.05) at 6 months, respectively. There were also significant decreases in serum level of bone formation marker (bone-specific alkaline phosphatase) and urinary excretion of bone resorption marker (deoxypyridinoline) at 3 and 6 months. Thus, alendronate showed anti-osteoporotic effects by increasing BMD and decreasing the concentrations of bone markers. The adverse events were mild and showed no significant difference between the two groups on safety assessments.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan, ROC.
authors.forename: Jawl-Shan
authors.initials: JS
authors.lastname: Hwang
authors.forename: Miaw-Jene
authors.initials: MJ
authors.lastname: Liou
authors.forename: Cheng
authors.initials: C
authors.lastname: Ho
authors.forename: Jen-Der
authors.initials: JD
authors.lastname: Lin
authors.forename: Yu-Yao
authors.initials: YY
authors.lastname: Huang
authors.forename: Chao-Jan
authors.initials: CJ
authors.lastname: Wang
authors.forename: Keh-Sung
authors.initials: KS
authors.lastname: Tsai
authors.forename: Jung-Fu
authors.initials: JF
authors.lastname: Chen
mesh_terms: D015502:Absorptiometry, Photon; D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D005272:Femur Neck / Q000737:chemistry; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008159:Lumbar Vertebrae / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D013624:Taiwan; D013997:Time Factors
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D007527:Isoenzymes; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase; D019386:Alendronate